Our Success 2006

11/13/2006
This week's Post-Marketing Patient Registries conference in Chicago re-affirmed the need for continued education and knowledge share regarding the utilization, development and tremendous benefits that can be obtained from both Patient and Product Registries. Attendees noted that the size and dynamics of the group were truly ideal for collaboration and information transfer. A solid conference program highlighting the many potential uses of patient registries, especially within unique populations differentiated this conference from others in the market and provided the information attendees were seeking. For additional program and conent feedback, click on the link below.
http://www.q1productions.com/events_Registries.html

11/01/2006
Q1 Productions had the opportunity to discuss upcoming trends and movements related to Post-Marketing Patient Registries with Ramita Tandon, a Director of Project Management for PAREXEL. Her insightful comments and industry expertise shine through as she discusses the challenges and great success that can be attained through implementing a Patient Registry. View the interview by clicking below:
Executive Interview with Ramita Tandon

9/25/2006
The recent Medical Device Clinical Trials conference, which took place this September 18-19 in Chicago reaffirmed the need for additional industry conferences and meetings relating to the individual challenges faced by the Device industry as they work to complete their clinical trials on time. A solid conference program highlighted the various hurdles that the industry faces and also provided strategic solutions to some of the most pressing issues. Attendees noted that the greatest benefit was truly being able to network with their peers in a setting that was developed specifically for the device industry, rather than trying to match their challenges to the pharmaceutical conferences in the market. For additional feedback on individual speakers at the confernece, click on the link below.
Click here for additional details

7/27/2006
Feedback from this weeks' Phase IV Conference in Philadelphia validated the continued need for Phase IV Clinical Research conferences within the industry. A robust conference program including a variety of topics and industry speakers enabled attendees to not only hear from industry experts, but spend time discussing important issues in an informal, learning atmosphere. Attendees noted that the greatest benefit of attendance was having a much higher number of registrants from the pharmaceutical industry as opposed to the provider market. This important balance, especially within the speaker program is a key value proposition that Q1 continually strives to maintain within our conference programs. For additional feedback on individual speakers at the conference, click on the link below!
Click herer for additional details

7/17/2006
Recently, Q1 Productions had the opportunity to sit down with Nayan Nanavati, the Vice President of the Peri-Approval Clinical Excellence group within PAREXEL to discuss the impact of increased post-marketing commitments within the pharmaceutical industry as well as the growth and development of Mr. Nanavati's division. For additional information on PAREXEL, please visit their website at www.PAREXEL.com. View the entire discussion by clicking on the link below.
Interview with Nayan Nanavati, VP Peri-Approval Clinical Excellence, PAREXEL

6/05/2006
Q1 Productions is pleased to annouce the expansion of their production, sales and marketing teams into a larger office space! For more information on our new, and historic, building, click here.

5/23/2006
The recent Risk Management in Adverse Events & Drug Safety conference took place this May 22-23 in Philadelphia and was of tremendous value to the industry executives that attended the program. Feedback was centered around relevant presentations from industry leaders, audience interactions that enabled attendees to directly question and challenge not only speakers but other attendees as well as practical approaches to challenges that drug safety executives face today. For more information regarding the content and speakers at this conference, click on the link below!
Click here for additional details

4/25/2006
At the recent Patient Reported Outcomes Research conference that took place April 24-24 in Arlington, Virginia, attendees really found what they were looking for. Feedback focused around a quality conference agenda highlighting the importance of a comprehensive understanding of the new FDA PRO guidance documents as well as business challenges associated with the use of PRO research in health economics and outcomes research. For more informaiton about the content and speakers that supported this program, click the PRO website link below.
Click here for additional details

3/6/2006
Q1 Productions recently sat down with Doug Hubbard, the President & CEO of Hubbard Decision Research to discuss the impact of the Applied Information Economics systems of benefit/risk analysis on not only large scale IT investments but also on complex decisions for investments in a wide portfolio of projects. For more information about Hubbard Decision Research, check out their website at www.hubbardresearch.com; or come out and meet Doug himself at the upcoming AIE Workshop to be held this April 24th in Washington, D.C. Download the full interview details by clicking on the link below.
Interview with Doug Hubbard, President & CEO of Hubbard Decision Research

2/20/2006
Q1 Productions had the opportunity to sit down with Doug Engfer, the Founder, President & CEO of invivodata, inc. to discuss the impact of Patient Reported Outcomes on the life science industry, trends and recent successes with the utilization of enhanced technologies, as well as the growth and development of this exciting organization. For more information about invivodata, check out their website at www.invivodata.com; or come out and meet them at the upcoming PRO Conference to be held this April 24-25 in Washington, D.C. Download the full interview details by clicking on the link below.
Interview with Doug Engfer, CEO of invivodata, inc.